Loading...
Market
What will be the objective response rate (ORR) of ivonescimab in a follow-up trial by end of 2025?
2
Resolution / Starting Odds
Above 55% • 25%
50-55% • 25%
45-50% • 25%
Below 45% • 25%
Results published in peer-reviewed journals or presented at medical conferences
Story
Summit Therapeutics' Ivonescimab Shows PFS of 11.14 Months, Outperforms Merck's Keytruda in PD-L1 Positive Lung Cancer Trial
Sep 8, 2024, 03:30 PM
At the 2024 World Conference on Lung Cancer (WCLC) in San Diego, Summit Therapeutics presented groundbreaking data from their Phase 3 HARMONi-2 trial. The trial revealed that ivonescimab, an investigational therapy, significantly outperformed Merck's Keytruda in treating patients with PD-L1 positive advanced non-small cell lung cancer (NSCLC). Ivonescimab demonstrated a median progression-free survival (PFS) of 11.14 months compared to 5.82 months for Keytruda, reducing the risk of disease progression or death by 49% (HR=0.51, p<0.0001). The objective response rate (ORR) was 50% for ivonescimab versus 38.5% for Keytruda. This data marks a historic achievement in the field of lung cancer treatment, potentially setting a new standard of care.
View original story
Similar markets
Less than 40% • 25%
40% to 50% • 25%
51% to 60% • 25%
More than 60% • 25%
Less than 10% • 25%
10%-20% • 25%
20%-30% • 25%
More than 30% • 25%
Less than 20% • 25%
20% to 30% • 25%
30% to 40% • 25%
Greater than 40% • 25%
Less than 30% • 25%
30% to 49% • 25%
50% to 69% • 25%
70% or higher • 25%
0-10% • 25%
11-20% • 25%
21-30% • 25%
Above 30% • 25%
Yes • 50%
No • 50%
Less than 40% • 25%
40% to 49% • 25%
50% to 59% • 25%
60% or more • 25%
Yes • 50%
No • 50%
Less than 50% • 25%
50% - 60% • 25%
60% - 70% • 25%
More than 70% • 25%
Less than 25% • 25%
25% to 30% • 25%
30% to 35% • 25%
More than 35% • 25%